Anus Neoplasms

• 

  Subject Areas on Research

  • A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. 
  • ACT II: treatment of anal cancer comes full circle. 
  • Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. 
  • Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. 
  • Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Anal cancer. American College of Radiology. ACR Appropriateness Criteria. 
  • Anal cancer: an overview. 
  • Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. 
  • Anal neoplasms. 
  • Anal-rectal cytology: a review. 
  • Anorectal melanoma: clinical characteristics and results of surgical management in twenty-four patients. 
  • Anorectal melanoma: clinical characteristics and the role of abdominoperineal resection. 
  • Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. 
  • Association of Interim FDG-PET Imaging During Chemoradiation for Squamous Anal Canal Carcinoma With Recurrence. 
  • Chemotherapy and radiation of anal canal cancer: the first approach. 
  • Cloacogenic carcinoma. 
  • Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. 
  • Current and emerging treatment strategies for anal cancer. 
  • Current management of anal canal cancer. 
  • Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. 
  • Emerging role of intensity-modulated radiation therapy in anorectal cancer. 
  • Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. 
  • Evolution and Management of Treatment-Related Toxicity in Anal Cancer. 
  • FDG PET/CT in the management of colorectal and anal cancers. 
  • Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. 
  • HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era. 
  • Human Papillomavirus-Related Cancer Surveillance, Prevention, and Screening Among Transgender Men and Women: Neglected Populations at High Risk. 
  • IMRT treatment of anal cancer with a scrotal shield. 
  • Immunohistochemical expression of p16 and Ki-67 correlates with degree of anal intraepithelial neoplasia. 
  • Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. 
  • Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). 
  • Integration of Anal Dysplasia Screening into the Primary Care of Persons Living with HIV. 
  • Intensity-modulated radiation therapy for anal cancer. 
  • Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. 
  • Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. 
  • Invasive squamous cell carcinoma of the anus arising in condyloma acuminatum: CT demonstration. 
  • Keratosis reduces sensitivity of anal cytology in detecting anal intraepithelial neoplasia. 
  • Laparoscopic intestinal stomas. 
  • Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. 
  • Lymphoscintigraphy for malignant melanoma. Surgical considerations. 
  • NCCN clinical practice guidelines in oncology. Anal carcinoma. 
  • Organ preservation in anal and rectal cancers. 
  • Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). 
  • RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. 
  • Radiation therapy advances for treatment of anal cancer. 
  • Radiation therapy in anal and rectal cancer. 
  • Role of pelvic chemoradiation therapy in patients with initially metastatic anal canal cancer: A National Cancer Database review. 
  • Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. 
  • Squamous cell carcinoma of the anal canal and anal margin. 
  • The use of an intrathecal pump to manage intractable cancer pain in a pediatric patient: a case report. 
  • Time-dose considerations in the treatment of anal cancer. 
  • US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. 
  • Unique Primary Care Needs of Transgender and Gender Non-Binary People. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • V-Y fasciocutaneous flap closure technique is a safe and efficacious alternative to primary closure of the perineal wound following abdominoperineal resection. 
  • p16 Improves interobserver agreement in diagnosis of anal intraepithelial neoplasia. 
• 

  Keywords of People

  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Yoo, Sua, Associate Professor of Radiation Oncology, Radiation Oncology